The Comparative Pathology Core is an established Core within the University of Pennsylvania School of Veterinary Medicine that has been integrated into the Abramson Cancer Center (ACC) and is presented as a newly established Shared Resource for NCI approval and CCSG funding. As such, the Core will enable the ACC to fulfill the growing needs of members who are using animal models. Amy Durham, MS, VMD, Diplomate of the American College of Veterinary Pathologists (DACVP) and Assistant Professor in the Department of Pathobiology at the School of Veterinary Medicine, developed and directs the Core. Dr. Durham is a board- certified anatomic veterinary pathologist with considerable experience in animal models of cancer, and has been involved in numerous collaborative research projects with members of the ACC and others throughout the Penn campus. Recognition and accurate interpretation of gross and histopathological lesions in animal models is essential for the success of cancer research. Currently, Core pathologists work with ACC members from multiple Research Programs, including Tumor Biology, Cancer Therapeutics, Breast Cancer, Immunobiology, Radiobiology and Imaging, and Pediatric Oncology. Among the services that have been provided are: mouse phenotyping, comprehensive slide evaluation and interpretation, consultation, autopsy training, and photomicroscopy. Additional services utilize the Core's histology laboratory to provide histopathology slide preparation, as well as special histochemical and immunohistochemical staining. Working with the Facility Director, Dr. Durham, is Dr. Elizabeth Buza, who is the Core's Technical Director and lead pathologist. Dr. Buza has expertise in mouse pathology and additional training in mouse models of disease from Novartis and Jackson Labs, and she has worked with Dr. Durham for several years. There are several board-certified anatomic pathologists who support Drs. Durham and Buza, and are available to provide specialty expertise depending on the investigator's particular needs. They include Dr. Julie Engiles (osteopathology), Dr. Elizabeth Mauldin (dermatopathology), and Dr. Melissa Snchez (oral pathology and immunohistochemistry). The Core currently serves 12 ACC members which, represents a doubling in ACC member usage since the announcement of the Core as an ACC Shared Resource in July 2013. Thus, as cancer research using mouse models continues to expand, Core utilization by ACC members is predicted to grow substantially.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-40
Application #
8998402
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
40
Fiscal Year
2016
Total Cost
$60,017
Indirect Cost
$22,506
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications